We are live on ! Find out more
NEPH icon

Nephros

36 hedge funds and large institutions have $9.5M invested in Nephros in 2026 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

6% more funds holding

Funds holding: 34 → 36 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

25.24% less ownership

Funds ownership: 49.01% → 23.77% (-25%)

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

76% less capital inflows, than outflows

Capital inflows: $3.38M | Capital outflows: $14.2M

Holders
36
Holders Change
+2
Holders Change %
+5.88%
% of All Funds
0.44%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
8
Increased
4
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NEPH Hedge Fund Activity: Q3 2026 in Review

36 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Nephros (NEPH) for Q3 2026, worth a combined $9.5M — down 50% from $19M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new NEPH positions and 6 closed out — a net gain of 2 holders — while 4 added to existing stakes and 10 trimmed.

The largest buyer was Massachusetts Institute of Technology, opening a new position worth an estimated $1.38M. The largest seller was Wexford Capital, cutting an estimated $13.5M.

  • 36 institutional investors held Nephros (NEPH) as of Q3 2026, up from 34 in Q2 2026.
  • Funds reported $9.5M of Nephros stock for Q3 2026, down 50% quarter-over-quarter.
  • 8 funds opened new Nephros positions in Q3 2026 and 6 closed out, a net change of +2 holders.
  • The largest Nephros buyer in Q3 2026 was Massachusetts Institute of Technology, an estimated $1.38M added.
  • The largest Nephros seller in Q3 2026 was Wexford Capital, an estimated $13.5M sold.

Based on aggregated 13F filings for Q3 2026.